MeiraGTx (MGTX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.
Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program.
The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases.
It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology.
MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Country | United States |
IPO Date | Jun 8, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 387 |
CEO | Dr. Alexandria Forbes Ph.D. |
Contact Details
Address: 430 East 29th Street New York, New York United States | |
Website | https://www.meiragtx.com |
Stock Details
Ticker Symbol | MGTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001735438 |
CUSIP Number | G59665102 |
ISIN Number | KYG596651029 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Alexandria Forbes Ph.D. | Chief Executive Officer, President & Director |
Richard Brian Giroux B.A. | Chief Operating Officer & Chief Financial Officer |
Christine Elise Sheehy | Senior Vice President of Global Integration |
Dr. Alastair Leighton Ph.D. | Senior Vice President of Manufacturing & Supply Chain |
Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology |
Dr. Robert K. Zeldin M.D. | Chief Medical Officer |
Dr. Stuart Naylor Ph.D. | Chief Development Officer |
Robert J. Wollin J.D. | General Counsel & Secretary |
Tim Randall | Senior Vice President of Risk & Internal Controls |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 21, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |